In a nutshell
This study characterized the safety and effectiveness of greenlight photo-selective vaporization of the prostate (GL-PVP) in the treatment of benign prostatic hyperplasia (BPH). The data showed that under real-world conditions, GL-PVP provides a safe, effective, and durable BPH treatment option.
Lower urinary tract symptoms (LUTS) commonly occur in men with BPH. The standard treatment is a surgery called transurethral resection of the prostate (TURP). However, bleeding is common with TURP. Minimally invasive techniques such as GL-PVP are alternatives to TURP.
GL-PVP involves the use of a laser to vaporize excessive tissue in enlarged prostates. Compared to TURP, GL-PVP results in minimal bleeding. There is a need to determine the current, global state of GL-PVP by data collection from international centers through the Global Greenlight Group (GGG) database.
Methods & findings
This study analyzed data from 3627 patients with LUTS secondary to BPH. All patients underwent GL-PVP using the XPS-180 W system. Data were evaluated up to 60 months.
The average prostate-specific antigen (PSA; a protein made by the prostate gland) level was 3.1 ng/mL. On average, there was a 43.9% PSA reduction at 3 months and a 46.4 % reduction at 60 months, after the procedure. The average time of the procedure was 34 minutes. In 60.1% of patients, the catheter was removed one day after the procedure.
Significant improvements in urinary symptoms and quality of life were seen at all timepoints during follow-up.
Most side effects were mild. 1.7% of patients experienced moderate and severe complications. 13.2% of patients had emergency room visits due to bloody urine. 10.5% of patients had urine leakage and 22.5% had urinary symptoms in the first month. After 6 months, 0.7% had urine leakage and 2.8% had urinary symptoms.
The bottom line
The study showed that GL-PVP is a safe and effective treatment alternative for LUTS secondary to BPH.
The fine print
The study design did not allow certain types of data to be collected and longer follow-ups are needed.
Published By :
World Journal of Urology
Apr 10, 2021
If you sign up for Medivizor, you'll receive PERSONALIZED updates that are JUST FOR YOU. Want to give it a try?